Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PulsenmorePLSM -6.70%25 Receivables Turnover is 10.58 as of Dec. 2025. GuruFocus rates PLSM with a GF Score™ of 25/100 and a GF Value™ of $8.16 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 813 Medical Devices & Instruments companies, Pulsenmore ranks better than 90.41% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pulsenmore's Revenue for the
six
months ended in Dec. 2025 was $11.91 Mil. Pulsenmore's average Accounts Receivable for the
six
months ended in Dec. 2025 was $1.13 Mil.
Hence, Pulsenmore's Receivables Turnover for the
six
months ended in Dec. 2025 was 10.58.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pulsenmore Receivables Turnover Related Terms
Pulsenmore Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pulsenmore's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLSM vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Pulsenmore's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulsenmore Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulsenmore's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pulsenmore's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulsenmore (PLSM) has a Receivables Turnover of 10.58 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pulsenmore and its competitors. According to the industry distribution chart, Pulsenmore ranks #78 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Pulsenmore's Receivables Turnover too high?
Pulsenmore's current Receivables Turnover is 10.58. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Pulsenmore's value of 10.58 is 92% above this industry median. Based on the distribution chart, Pulsenmore ranks #78 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pulsenmore has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulsenmore's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Pulsenmore ranks #78 out of 813 companies for Receivables Turnover. This places Pulsenmore in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Pulsenmore's value of 10.58 is 92% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulsenmore's current Receivables Turnover of 10.58 is 92% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pulsenmore and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulsenmore's current Receivables Turnover is 10.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulsenmore stock overvalued right now?
Based on GuruFocus' analysis, Pulsenmore (PLSM) is currently considered Possible Value Trap. The stock's GF Value™ is $8.16, compared to a current price of $3.60 — trading 55.9% below its estimated fair value. The current Receivables Turnover is 10.58 and 92% above the Medical Devices & Instruments industry median of 5.51. Pulsenmore's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pulsenmore (PLSM), the current Receivables Turnover is 10.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulsenmore (PLSM) Overvalued in 2026?
Based on GuruFocus' analysis, Pulsenmore stock appears to be undervalued.
The current stock price of $3.60 is trading 55.9% below its estimated GF Value™ of $8.16.
GuruFocus considers Pulsenmore to be Possible Value Trap.
Key valuation signals for PLSM:
Receivables Turnover: 10.58
GF Value™: $8.16 vs. price of $3.60 (55.9% below fair value)
Industry Position: 92% above the Medical Devices & Instruments median (#78 of 813)
No single metric tells the full story. See the PLSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
25GF Score
Get the complete analysis for PLSM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSM has been successfully added to your 
